熱門資訊> 正文
Amylyx Pharmaceuticals GAAP每股收益为-1.07美元
2024-08-08 20:48
- Amylyx Pharmaceuticals press release (NASDAQ:AMLX): Q2 GAAP EPS of -$1.07.
- Cash, cash equivalents, and short-term investments were $309.8 million at June 30, 2024, compared to $373.3 million at March 31, 2024.
More on Amylyx Pharmaceuticals
- Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
- Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
- Amylyx jumps on acquisition of Eiger’s GLP-1 drug
- Amylyx inks deal to buy Eiger’s GLP-1 targeting drug
- Seeking Alpha’s Quant Rating on Amylyx Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
